ImmuPharma (LON:IMM) Shares Down 31.4% – Here’s Why

Shares of ImmuPharma plc (LON:IMM) traded down 31.4% on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares were traded during mid-day trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.

ImmuPharma Trading Down 31.4%

The stock has a market cap of £33.68 million, a P/E ratio of -7.53 and a beta of 1.53. The stock’s 50-day moving average is GBX 10.96 and its 200-day moving average is GBX 5.84.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.